Abstract
Full text links
Read article at publisher's site: https://doi.org/10.1146/annurev-pathol-012615-044224
References
Articles referenced by this article (305)
AGA technical review on nonalcoholic fatty liver disease.
Gastroenterology, (5):1705-1725 2002
MED: 12404245
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.
Ann Med, (8):617-649 2010
MED: 21039302
Long-term follow-up of patients with NAFLD and elevated liver enzymes.
Hepatology, (4):865-873 2006
MED: 17006923
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.
Hepatology, (2):419-428 2011
MED: 22006541
Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease.
Hepatology, (5):1593-1602 2010
MED: 20222092
Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.
Gastroenterology, (1):85-94 2007
MED: 18005961
Nonalcoholic fatty liver disease: a review of current understanding and future impact.
Clin Gastroenterol Hepatol, (12):1048-1058 2004
MED: 15625647
Show 10 more references (10 of 305)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1146/annurev-pathol-012615-044224
Article citations
Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review.
Arch Toxicol, 23 Oct 2024
Cited by: 0 articles | PMID: 39443317
Review
Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice.
Front Med (Lausanne), 11:1476419, 08 Oct 2024
Cited by: 0 articles | PMID: 39440040 | PMCID: PMC11493624
Review Free full text in Europe PMC
Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital.
Cells, 13(20):1707, 16 Oct 2024
Cited by: 0 articles | PMID: 39451225 | PMCID: PMC11505720
Pathogenesis and research progress of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Hepatol, 16(10):1142-1150, 01 Oct 2024
Cited by: 0 articles | PMID: 39474575 | PMCID: PMC11514618
ER-mitochondria contact sites regulate hepatic lipogenesis via Ip3r-Grp75-Vdac complex recruiting Seipin.
Cell Commun Signal, 22(1):464, 30 Sep 2024
Cited by: 0 articles | PMID: 39350150 | PMCID: PMC11440722
Go to all (278) article citations
Other citations
Wikipedia
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Adv Exp Med Biol, 1261:223-229, 01 Jan 2021
Cited by: 7 articles | PMID: 33783745
Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Oncotarget, 7(27):42762-42776, 01 Jul 2016
Cited by: 18 articles | PMID: 27072576 | PMCID: PMC5173170
Review Free full text in Europe PMC
The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Am J Physiol Gastrointest Liver Physiol, 319(3):G345-G360, 05 Aug 2020
Cited by: 12 articles | PMID: 32755310 | PMCID: PMC7509261
The role of the microbiome in NAFLD and NASH.
EMBO Mol Med, 11(2):e9302, 01 Feb 2019
Cited by: 242 articles | PMID: 30591521 | PMCID: PMC6365925
Review Free full text in Europe PMC
Funding
Funders who supported this work.
Medical Research Council (1)
The role of DNA Methylation as an epigenetic modifier of hepatic fibrosis progression in Non Alcoholic Fatty Liver Disease.
Dr Timothy Hardy, Newcastle University
Grant ID: MR/L002094/1